← All trials
NCT06993103
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 2, 2025
- Primary completion
- Apr 30, 2028
- Completion date
- Dec 31, 2028
- First posted
- May 28, 2025
- Last posted
- May 28, 2025
- Enrollment
- 1444
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of QueenslandLead sponsor
- Australian Red CrossCollaborator
- University of QueenslandCollaborator
- La Trobe UniversityCollaborator
- South Australian Health and Medical Research InstituteCollaborator
- University of MelbourneCollaborator
- University of MelbourneCollaborator
- Murdoch UniversityCollaborator
- Monash UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.